Octreotide an analogue of somatostatin with a more favorable pharmacok
inetic profile is a new drug that may offer some advantages in the pal
liative care setting. It has been used with favorable results in the m
anagement of some gastrointestinal disorders, such as gastrointestinal
hemorrhage, diarrhea, short-bowel syndrome, fistula, and intestinal o
cclusion in the palliative care setting. These favorable results occur
red without important side effects, underlining the potential role of
this drug. The cost-benefit ratio of this expensive drug must be consi
dered, however.